In an interview to Izvestia newspaper, Professor Andrei Simbirtsev, Deputy Director of the Federal Medical-Biological Agency (FMBA) of Russia, Doctor of Medical Sciences, Corresponding Member of RAS, said that the institute is completing preclinical trials of a medicine that may revolutionize the oncology.
„Our drug has working title “Heat Shock Protein” based on its main active ingredient. It is a molecule synthesized by human body cells in response to various stress conditions,“ said Mr. Simbirtsev.
According to the scientist, this protein helps a cell to present its tumor antigens to the immune system, thereby strengthening the anti-tumor immune response. The experiments have shown that, in most cases, the course of treatment with the investigational drug resulted in complete cure even at the later stages. This fundamentally new tool in the fight against malignant tumors was obtained using biotechnology and space experiment conducted on the International Space Station in 2015.
Given that the new medicine is in final stages of preclinical trials, it is expected to become available to patients within 3-4 years. However, the issue entirely depends on whether the scientists will be able to find a source of funding.